Endpoints News

Gene therapy biotech gets €33M		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

7 July, 2026

news

Vertex makes $10B deal for commercial endocrinology biotech Crinetics

French gene therapy biotech gets €33M to follow Krystal's blueprint

FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

sponsored by GUARDANT

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

ENDPOINTS PHARMA

CMS proposes 340B cuts

New acting deputy CDER promotion elevates longtime GLP-1 reviewer

Roche's $25M Astex deal is small money upfront, but a big signal for breast cancer goals

in case you missed it

Bristol Myers details Krazati confirmatory study failure in colorectal cancer

Updated: Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform

Salk Institute’s president on NIH cuts, being ‘all in’ on AI, and the Year of the Brain

News Briefing

Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot

Trump’s drug price crusade puts Europe on guard

How easy is it to get weight-loss drugs online? Secret shoppers from Yale found out.

Vertex unveiled its big move yesterday afternoon with plans to buy Crinetics and its drug for acromegaly plus a portfolio of clinical-stage endocrinology drugs. Read more from Kyle LaHucik here.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio
Endpoints Webinars

Endpoints Events
Biopharma Jobs

Worldwide made. Thanks for reading.

Unsubscribe preferences

Unsubscribe from all newsletters